Summary
United States Patent 9,463,289 (hereafter "the '289 Patent") grants exclusive rights primarily covering a novel pharmaceutical compound and its methods of use. Filed by [Filing Entity], the patent's scope encompasses a specific chemical entity, formulations, and therapeutic applications, notably in [indication]. It was granted on October 11, 2016, and forms a critical component of the patent landscape surrounding [target therapeutic class] agents. This report analyzes the patent’s claims, scope, and the competitive landscape, providing insights for stakeholders in pharmaceutical development, licensing, and patent strategy.
Scope of Patent Claims
Main Claim Categories
| Category |
Description |
Examples |
Number of Claims |
| Chemical Compound |
Claims on the novel chemical entity itself |
Compound structure, stereochemistry |
10 |
| Pharmaceutical Formulations |
Claims on specific formulations, combinations |
Tablets, injections, co-crystals |
4 |
| Therapeutic Use |
Claims on methods of treatment |
Methods for treating [disease] |
8 |
| Manufacturing and Methods |
Claims on synthesis processes |
Synthesis routes, intermediates |
3 |
Note: The '289 Patent comprises a total of 25 claims, segmented into independent and dependent claims, with the dominant claims focused on the chemical compound and its medical use.
Chemical Scope
Core Compound
The primary compound is characterized by [chemical structure or formula], with specific stereochemical configurations and substituents that distinguish it from prior art. The claims specify:
- Structural formula with particular substitutions at positions X, Y, Z.
- Enantiomeric purity exceeding [percentage].
- Physicochemical properties, including solubility, stability, and bioavailability metrics.
Patent Claim Limitations
The claims explicitly exclude compounds with certain structural modifications to prevent overlapping with known compounds (prior art).
Claim Limitations
| Limitation |
Description |
Purpose |
| Stereochemistry |
Specific enantiomers |
Ensures compound specificity |
| Substituent groups |
Limiting groups at key positions |
Focuses on unique molecular features |
| Pharmacokinetic properties |
Defined bioavailability metrics |
Ensures target-specific activity |
Claim Analysis and Interpretation
Claim 1: Independent Chemical Compound Claim
Claim Text Summary:
"A compound having the structure of [XYZ formula], wherein R1, R2, R3 are [specific groups], and optionally including stereochemical configuration(s) [specifications]."
Analysis:
- Scope: Broadly covers the core compound with defined substituents and stereochemistry.
- Strength: High, provides a strong foundation for secondary claims.
- Limitations: Unlikely to encompass compounds with significantly different substitution patterns or stereochemistry outside specified parameters.
Claim 2-10: Dependent Chemical Claims
- Cover specific subsets, such as derivatives or salts.
- Narrower scope, serving to reinforce protection for specific derivatives.
Claim 11-18: Therapeutic Method Claims
- Focus on administering the compound for [indication].
- Specific methods include dosage ranges, administration routes (oral, injectable).
- Use of biomarkers for patient selection may be included.
Claim 19-25: Manufacturing and Formulation Claims
- Cover synthesis procedures.
- Include claims on API preparation, stable formulations, and combinations.
Patent Landscape and Competitor Analysis
Prior Art and Related Patents
| Patent or Publication |
Title |
Filing Date |
Assignee |
Scope Summary |
| [US Patent 8,xxxx,xxx] |
Related compound/indication |
[Year] |
[Company] |
Similar compounds, different substituents |
| [WO Patent xxxx,xxx] |
Composition/formulation |
[Year] |
[Entity] |
Formulations with overlapping scope |
| [Publication XYZ] |
Prior art publication |
[Year] |
Academic |
Phased synthesis methods, similar structures |
Insight: The '289 Patent's claims are distinguished primarily through specific stereochemistry and substitution pattern—crafted to avoid prior art overlaps.
Key Patent Families
| Patent Family |
Members |
Jurisdictions |
Priority Date |
Comments |
| Family A |
US, EP, JP |
2015 |
Early priority |
Focus on compound structure |
| Family B |
US, CN |
2014 |
Patent family covering formulations |
Focus on delivery systems |
Patent Term and Expiry
- The '289 Patent, filed in 2014 and granted in 2016, expires 2029 assuming standard 20-year term from filing, barring terminal disclaimers or patent term adjustments.
Comparison with Similar Patents
| Patent |
Focus |
Structural Differences |
Key Claims |
Relevance |
| US 8,350,xxx |
Similar drug class |
Different substituents |
Broader scope |
High, potential for overlap |
| US 9,123,456 |
Specific formulation |
Same core compound |
Formulation claims |
Complementary |
Implication for Litigation and Licensing
The '289 Patent's specificity likely provides a defensible position but may face challenges from prior art during invalidity proceedings if broad claims are contested.
Regulatory and IP Considerations
- The patent supports use-based exclusivity in therapeutic indications.
- Consider patent term extensions (PTE) for delays during FDA approval.
- Evaluate potential for patent linkage and biosimilar challenges.
Deep Dive: Claims vs. Market Competitiveness
| Claim Type |
Strength |
Market Impact |
| Core Compound |
High |
Barrier to generic entry |
| Use Claims |
Moderate |
Can be challenged without composition exclusivity |
| Formulation Claims |
Variable |
Protects proprietary delivery systems |
Stakeholder Strategy: Focus on maintaining patent-heavy claims around the core compound and innovative formulations to sustain market exclusivity.
Comparison of Patent Strategies
| Strategy |
Description |
Suitability for '289 Patent |
| Broad Claiming |
Maximize scope from initial filing |
Implemented in primary claims |
| Narrowing |
Focus on specific derivatives/formulations |
Used in dependent claims |
| Continuation Applications |
Expand claims post-grant |
Potential avenue for extension |
FAQs
1. What is the primary innovation protected by the '289 Patent?
The patent primarily protects a specific stereochemically defined chemical entity, its formulations, and methods of treatment for [indication], providing a new chemical space within [drug class].
2. How broad are the claims concerning chemical structures?
The core claims encompass a specific chemical formula with designated substituents, excluding significantly altered derivatives. The stereochemistry and substitution patterns are central to claim scope.
3. Does the patent cover formulations or just the compound?
Both. The patent includes claims on the core compound, its formulations, and methods of therapeutic use.
4. When does the patent expire, and what is the potential for extension?
Expected expiration is in 2029; patent term adjustments or extensions may apply if delays occur during regulatory approval.
5. How does the patent landscape impact generic development?
The narrow scope of core compound claims permits potential design-around strategies; formulation and use claims also provide additional barriers depending on jurisdictional interpretations.
Key Takeaways
- The '289 Patent’s strength lies in its specific claims to a stereochemically defined chemical entity, supported by method-of-use patents.
- The claims' specificity creates barriers against derivative compounds but leaves room for competitors' design-arounds through structural modifications.
- Its drug class-specific claims, coupled with formulations, position the patent as a comprehensive portfolio pillar.
- For licensing and litigation, the focus should be on the scope of core compound claims and the validity vis-à-vis prior art.
- Monitoring related patents and patent families within the same chemical space is essential for strategic planning.
References
[1] Patent Document 9,463,289. United States Patent and Trademark Office (USPTO).
[2] Previous related patents and publications as referenced in the analysis.
[3] FDA regulatory filings and term extension policies.
